论文部分内容阅读
目的观察重组人血管内皮抑制素(恩度)联合NP对比单纯用NP方案治疗晚期非小细胞肺癌疗效及不良反应。方法治疗组用恩度+NP,对照组单纯用NP,治疗晚期非小细胞肺癌33例,治疗2~4周期,观察疗效及不良反应。结果治疗组与对照组有效率分别为37.5%和23.5%(P<0.05),疾病控制率为75.0%和64.7%;不良反应主要有白细胞及血小板减少,两组比较差异均无统计学意义(P>0.05)。结论恩度联合NP方案具有协同作用,能显著提高晚期非小细胞肺癌的有效率和疾病控制率,且安全性好,长期疗效需进一步观察。
Objective To observe the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with NP compared with NP alone in the treatment of advanced non-small cell lung cancer. Methods Endostar + NP was used in the treatment group, 33 cases of advanced non-small cell lung cancer were treated with NP alone in the control group, and the curative effect and adverse reaction were observed. Results The effective rates of the treatment group and the control group were 37.5% and 23.5% (P <0.05), and the disease control rates were 75.0% and 64.7%. The main adverse reactions were leukopenia and thrombocytopenia. There was no significant difference between the two groups P> 0.05). Conclusions Endood combined with NP regimen has a synergistic effect, which can significantly improve the efficiency and disease control rate of advanced non-small cell lung cancer. The safety and long-term efficacy need further observation.